13:41:40 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Vector Science and Therapeutics Corp.
Symbol PAIN
Shares Issued 157,322,930
Close 2026-11-13 C$ 2.89
Market Cap C$ 454,663,268
Recent Sedar+ Documents

ORIGINAL: Sports Medicine Pioneer Dr. James Andrews and Vector Chairman Tommy Thompson, former U.S. Secretary of Health and Human Services, to Announce Major Medical Development Involving Peptides

2026-11-16 07:30 ET - News Release

Sports Medicine Pioneer Dr. James Andrews and Vector Chairman Tommy Thompson, former U.S. Secretary of Health and Human Services, to Announce Major Medical Development Involving Peptides

PR Newswire

Pre-registration is open for Zoom event set for 11 a.m. CST on Wednesday, Nov. 18

TORONTO, Nov. 16, 2026 /PRNewswire/ -- Dr. James Andrews, a world-renowned orthopedic surgeon and sports medicine pioneer, and Tommy G. Thompson, the former U.S. Secretary of Health and Human Services and current Chairman of Vector Science and Therapeutics Corp. (TSXV: PAIN), will host a livestreamed media briefing from Gulf Breeze, Fla., on Wednesday, Nov. 18. Dr. Andrews and Mr. Thompson will announce a major medical development involving peptides in the United States.

Livestreamed Media Briefing Information

Date: Wednesday, Nov. 18, 2026

Time: 11 a.m. to 11:30 a.m. CST

Format: Live Zoom event originating in Gulf Breeze, Fla.

Pre-registration and event access: https://russopr.zoom.us/webinar/register/WN_N_YU_AHMT-yOZk4iSdK41w

Journalists and other audience members should use the Zoom link above to pre-register. Following registration, attendees will receive the information needed to access the live event.

Media Interview Scheduling and Coordination

Immediately following the briefing, from 11:30 a.m. CST until 12:30 p.m. CST on Wednesday, Dr. Andrews, Mr. Thompson, and other briefing participants will be available to conduct media interviews via Zoom or telephone. Interview requests and scheduling will be handled through the chat function during the Zoom event or by email using VectorPR@russopartnersllc.com. Journalists who are unable to conduct interviews during this window may request additional times, and Russo Partners will manage these requests individually.

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology company advancing anatomically focused drug delivery technology and cGMP-manufactured Rx peptides for the sports medicine, regenerative medicine, pain management, and wound care markets. Vector's peptides are manufactured using pharma-grade Active Pharmaceutical Ingredients (API) from qualified suppliers and are produced under current Good Manufacturing Practice (cGMP) and ISO-certified quality systems.

The Company's product and intellectual property portfolio includes advanced transdermal delivery, precision catheter systems and smart wound care technologies. Vector is headquartered in Mequon, Wis. For more information, visit https://vectorscience.co/. Follow Vector on LinkedIn and X.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sports-medicine-pioneer-dr-james-andrews-and-vector-chairman-tommy-thompson-former-us-secretary-of-health-and-human-services-to-announce-major-medical-development-involving-peptides-302940007.html

SOURCE Vector Sciences & Therapeutics

Contact:

Media Contacts: David Schull or Elio Ambrosio, Russo Partners, Email: VectorPR@russopartnersllc.com, Phone: (858) 717-2310

© 2026 Canjex Publishing Ltd. All rights reserved.